Biodexa Pharmaceuticals (BDRX) Asset Utilization Ratio (2018 - 2019)
Biodexa Pharmaceuticals' (BDRX) quarterly Asset Utilization Ratio came in at 0.56 in Q4 2019, down 32.91% year-over-year from 0.83 in Q4 2018, and down 32.91% quarter-over-quarter from 0.83 in Q4 2018.
Powered by 
Analysis
Biodexa Pharmaceuticals (BDRX) Asset Utilization Ratio (2018 - 2019) Analysis & Trends
Biodexa Pharmaceuticals has disclosed Asset Utilization Ratio across 2 years of filings, most recently posting 0.56 for Q4 2019.
- In Q4 2019, Asset Utilization Ratio fell 32.91% year-over-year to 0.56; the TTM figure through Dec 2019 stood at 0.56 (down 32.91% YoY), while the FY2023 annual figure was 0.05, down 32.44% from the prior year.
- Asset Utilization Ratio came in at 0.56 for Q4 2019 at Biodexa Pharmaceuticals, down from 0.83 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.83 in Q4 2018 to a low of 0.56 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 180.97 Bn | 177.80 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 132.56 Bn | 124.70 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 82.34 Bn | 74.34 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 60.73 Bn | 55.54 Bn | 1.37 Bn | - |
| 6 | Moderna | 52.08 Bn | 46.95 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 33.90 Bn | 30.59 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.21 Bn | 29.93 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 29.68 Bn | 29.68 Bn | 1.16 Mn | 0.00 |
| 10 | Biodexa Pharmaceuticals | 49.28 Mn | 37.93 Mn | - | - |